PRINCETON, N.J. and SUZHOU, China, October 31, 2025 -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announced its partner Inhibrx Biosciences, Inc. ("Inhibrx") (Nasdaq: INBX), has reported positive topline results from the registrational ChonDRAgon study (n= 206) investigating ozekibart (INBRX-109) as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma. Based on these results, Inhibrx has stated it intends to file for US approval in chondrosarcoma by the end of June 2026. Transcenta holds the exclusive rights to develop and commercialize ozekibart (INBRX-109) in mainland China, Hong Kong SAR, Macau SAR, and Taiwan region under a license agreement executed through HJB (Hangzhou) Co., Ltd * (杭州奕安济世生物药业有限公司) (“HJB”), a wholly owned subsidiary of Transcenta Holding.

Ozekibart is the first investigational therapy to demonstrate a significant PFS benefit in a randomized trial for chondrosarcoma, a disease with no approved systemic options. These encouraging clinical data provide additional confirmation of the value of this asset for patients around the world and the territories in which Transcenta holds exclusive rights.

About Ozekibart (INBRX-109)

Ozekibart is a precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody designed to exploit the tumor-biased cell death induced by DR5 activation. In January 2021, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to ozekibart for the treatment of patients with metastatic or unresectable conventional chondrosarcoma, and, in November 2021, the FDA granted orphan drug designation to ozekibart for chondrosarcoma.

In addition to the registrational trial, Inhibrx is advancing ongoing expansion cohorts, evaluating ozekibart in combination with irinotecan-based regimens in Ewing sarcoma and colorectal cancer. Encouraging early signals support further exploration of ozekibart's potential in these difficult-to-treat tumor types with high unmet medical need.

About Transcenta

Transcenta (HKEX: 06628) is a clinical stage biopharmaceutical company with fully integrated capabilities in antibody-based biotherapeutics discovery, research, development and manufacturing.

Transcenta has established global footprint, with Headquarters and Discovery, Clinical and Translational Research Center in Suzhou, Process and Product Development Center and Manufacturing Facility in Hangzhou, and Clinical Development Centers in China, U.S. and Europe. Transcenta is developing 16 therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders.

For more information, please visit www.transcenta.com and https://www.linkedin.com/company/transcenta. For inquiries regarding capital cooperation opportunities, please contact us at ir@transcenta.com